Medical Device User Fee and Modernization Act
Generated by GPT-5-miniExpansion Funnel Raw 41 → Dedup 0 → NER 0 → Enqueued 0
| Medical Device User Fee and Modernization Act | |
|---|---|
| Name | Medical Device User Fee and Modernization Act |
| Enacted by | United States Congress |
| Effective date | 2002 |
| Signed by | George W. Bush |
| Related legislation | Food and Drug Administration Modernization Act, Food and Drug Administration Amendments Act of 2007, Food and Drug Administration Safety and Innovation Act |
| Status | enacted |
Medical Device User Fee and Modernization Act The Medical Device User Fee and Modernization Act (MDUFMA) is a 2002 statute that authorized the Food and Drug Administration to collect fees from medical device manufacturers to fund premarket review processes and postmarket activities. The statute intersects with prior and subsequent statutes affecting public health oversight, including initiatives led by the Department of Health and Human Services and executive actions under United States presidential administrations. MDUFMA reshaped interactions among regulators, industry trade groups such as the Advanced Medical Technology Association, and litigants bringing challenges under statutes like the Administrative Procedure Act.
Background and Legislative History
MDUFMA emerged amid debates in the late 1990s and early 2000s involving the Food and Drug Administration Modernization Act reforms, congressional committees including the United States Senate Committee on Health, Education, Labor, and Pensions, and stakeholders such as the Medical Device Manufacturers Association and consumer advocates like Public Citizen. The legislative process involved hearings featuring testimony from officials from the Food and Drug Administration, executives from firms like Medtronic and Boston Scientific, and experts affiliated with institutions such as the Johns Hopkins School of Medicine and the Centers for Disease Control and Prevention. Concerns about review backlogs, exemplified in disputes recorded in the Federal Register and raised during debates in the United States House Committee on Energy and Commerce, motivated Congress to authorize user fees modeled after fee programs in statutes like the Prescription Drug User Fee Act.
Provisions and Program Structure
MDUFMA established categories of fees tied to application types handled by the Food and Drug Administration's Center for Devices and Radiological Health. Key programmatic provisions included timelines for performance goals, mechanisms for fee collection administered by the Department of the Treasury, and reporting requirements to the Congressional Budget Office and the Office of Management and Budget. The law created obligations for fee-paying entities, exemptions for small businesses defined in consultation with the Small Business Administration, and provisions for user fee negotiations overseen by FDA leadership and representatives from industry groups such as the Advanced Medical Technology Association.
Fee Schedule and Revenue Allocation
The statute specified fee categories—premarket application fees, establishment registration fees, and product fees—establishing a schedule adjusted annually through rulemaking and consultations with the Office of Management and Budget and the Congressional Budget Office. Revenue allocation earmarked funds for expanded staffing within the Food and Drug Administration's review divisions, investments in information technology systems like those used by the National Institutes of Health and the Centers for Medicare & Medicaid Services, and activities such as postmarket surveillance coordinated with agencies including the Agency for Healthcare Research and Quality. Fee waivers and reductions were structured in relation to criteria administered by the Small Business Administration and entities represented by the National Small Business Association.
Impact on FDA Regulation and Review Timelines
Implementation of MDUFMA correlated with measurable changes in performance metrics reported by the Food and Drug Administration, including median review times for applications overseen by the Center for Devices and Radiological Health and rates of meeting review goals published in the Federal Register. The infusion of resources enabled hiring of reviewers with backgrounds from institutions such as the Mayo Clinic and the National Institutes of Health, adoption of electronic submission platforms similar to systems used by the United States Patent and Trademark Office, and enhanced postmarket programs coordinated with the Centers for Disease Control and Prevention. Critics and supporters debated the relationship between fee-funded capacity and decisions affected by standards articulated in precedents from the United States Court of Appeals for the Federal Circuit.
Stakeholder Responses and Legal Challenges
Industry associations including the Advanced Medical Technology Association and companies like Johnson & Johnson largely supported the statute for its promise of predictable review timelines, while consumer organizations such as Public Citizen and patient advocacy groups including the American Heart Association raised concerns about regulatory independence. Litigation citing the Administrative Procedure Act and constitutional claims appeared in filings before district courts and appeals courts, with amici briefs from organizations such as the American Medical Association and academic centers including Harvard Medical School. Congressional oversight hearings convened by the United States Senate Committee on Health, Education, Labor, and Pensions scrutinized fee use and performance reporting.
Amendments, Reauthorizations, and Subsequent Legislation
MDUFMA was followed by reauthorizations and statutory changes through measures like the Food and Drug Administration Amendments Act of 2007 and the Food and Drug Administration Safety and Innovation Act, which expanded user fee programs and modified performance goals. Subsequent legislative actions in the United States Congress updated fee schedules, refined small business provisions in coordination with the Small Business Administration, and incorporated recommendations from reviews by the Government Accountability Office. The evolution of device user fee law continues to interact with regulatory developments at the Food and Drug Administration and judicial interpretations from the United States Supreme Court and federal appellate courts.